MarginsXMarginsX
Home › Markets › Health Care › UTHR

United Therapeutics Corporation (UTHR)

UTHR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$587.88
-0.56% on the day
Market cap
$25.0B
Large cap
Revenue · 2025
$3.2B
+10.6% on 2024
Net income · 2025
$1.3B
41.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1082554/000108255426000006/0001082554-26-000006-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerUTHR on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year1999
SEC CIK0001082554
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$3.2B
Net income$1.3B
Operating income$1.5B
Net margin41.9%
Operating margin46.9%
Revenue growth+10.6%
Cash$1.6B
Total assets$7.9B
P/E (computed)18.8×
P/S (computed)7.9×

Warning signs

Cash runway
Cash-flow positive
$1.2B cash at September 30, 2026
Share count, 1 year
-1.1%
2025-10-22 to 2026-10-28 · -9.4% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$1.4B
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$1.2B cash; operating cash flow $357.4M a quarter.Report 2026-09-30
Shares outstanding42,588,726 (2026-10-28); 43,056,599 a year earlier; 46,993,601 three years earlier.Cover page 2026-10-28
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Tysons, Virginia, United StatesPCAOB Form AP 2026-03-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $864K, sold $1.4B on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$832.5M$258.6M$306.5M$1.2BNo debt tags$3.2B10-Q 2026-11-04
Q2 2026
2026-06-30
$783.3M$333.0M$313.6M$1.8BNo debt tags$3.2B10-Q 2026-08-05
Q1 2026
2026-03-31
$781.5M$274.9M$463.3M$1.3BNo debt tags$3.2B10-Q 2026-05-06
Q4 2025
2025-12-31
$790.2M$364.3M$346.2M$1.6BNo debt tags$3.2B10-K 2026-02-25
Q3 2025
2025-09-30
$799.5M$338.7M$562.1M$1.3BNo debt tags$3.1B10-Q 2026-11-04
Q2 2025
2025-06-30
$798.6M$309.5M$191.7M$1.6BNo debt tags$3.1B10-Q 2026-08-05
Q1 2025
2025-03-31
$794.4M$322.2M$461.2M$1.9BNo debt tags$3.0B10-Q 2026-05-06
Q4 2024
2024-12-31
$735.9M$301.3M$341.2M$1.7BNo debt tags$2.9B10-K 2026-02-25

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest annual report10-K2026-02-25
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-04
Latest proxy
DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS
DEFA14A2026-04-29

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+5.2%
1 month+8.8%
3 months+17.9%
Year to date+21.3%
1 year+27.9%
From 52-week high-2.8%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
VTRSViatris Inc.$20.74-0.38%$23.8B
INSMInsmed Incorporated$122.88+1.42%$27.0B
ROIVRoivant Sciences Ltd. Common Shares$38.61-2.33%$28.0B
ALNYAlnylam Pharmaceuticals Inc.$159.73-3.22%$21.4B
GMABGenmab A/S ADS$51.57+0.39%$32.2B
ZTSZoetis Inc.$84.39+0.68%$34.3B
ASNDAscendis Pharma A/S Ordinary Share$271.73-1.33%$17.9B
RPRXRoyalty Pharma plc Class A Ordinary Shares$68.53-1.13%$39.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier